XML 54 R36.htm IDEA: XBRL DOCUMENT
v3.24.3

Earnings per share | 12 Months Ended
--- | ---
Jun. 30, 2024
Text block [abstract] |
Earnings per share | Note 31. Earnings per share
|  | 2024 A$‘000 |  |  | 2023 A$‘000 |  |  | 2022 A$‘000 |
Earnings per share for losses from continuing operations |  |  |  |  |  |  |  |  |  |  |  |
Loss after income tax attributable to the owners of Kazia Therapeutics Limited |  |  | (26,778 | ) |  |  | (20,465 | ) |  |  | (25,014 | )
Loss after income tax attributable to the owners of Kazia Therapeutics Limited |  |  | (26,778 | ) |  |  | (20,465 | ) |  |  | (25,014 | )
|  | Number |  |  | Number |  |  | Number |
Weighted average number of ordinary shares used in calculating basic and diluted earnings per share |  |  | 263,676,313 |  |  |  | 184,284,350 |  |  |  | 132,467,686 |
|  | Cents |  |  | Cents |  |  | Cents |
Basic and diluted earnings per share |  |  | (10.16 | ) |  |  | (11.23 | ) |  |  | (18.88 | )
The number of unissued shares under option that have been excluded from the diluted EPS are 36,180,000 (2024), 14,780,000 (2023), and 8,655,500 (2022).

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 33 -IssueDate 2023-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfEarningsPerShareExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block [abstract] + References No definition available. + Details
Name: | kzia_TextBlockAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration